ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements with these filters
Camlin Fine Sciences filed a Postal Ballot Notice seeking approval to appoint Mr. Atul Pradhan as Non-Executive Independent Director. E-voting runs September 17 to October 16, 2026.
Camlin Fine Sciences appointed Mr. Atul Pradhan as Additional Non-Executive Independent Director effective September 11, 2026. The appointment is subject to shareholder approval via postal ballot.
Camlin Fine Sciences reported Q1 FY27 revenue of INR 5,199 million, up 28% YoY, though EBITDA margins were pressured to 4% by high raw material and freight costs.
Camlin Fine Sciences reported record quarterly revenue of Rs 5,199 Mn for Q1FY27, up 27.5% YoY, driven by strong growth in Specialty Ingredients and Aroma segments.
Camlin Fine Sciences Ltd reported revenue from operations of ₹519.9 Cr (+27.5% YoY) and a net loss of ₹33.6 Cr for Q1 FY27.
Camlin Fine Sciences Limited held its 33rd Annual General Meeting on August 11, 2026. All resolutions proposed in the notice were passed by the shareholders.
Camlin Fine Sciences Limited will hold a board meeting on August 11, 2026. The board will consider and approve un-audited financial results for the quarter ended June 2026.
Promoter Ashish Subhash Dandekar released a pledge of 4,000 equity shares of Camlin Fine Sciences Ltd. This release followed the repayment of borrowings by the company.
Camlin Fine Sciences informed shareholders about the upcoming 33rd Annual General Meeting and the availability of the Annual Report 2025-26 on its website.
Camlin Fine Sciences Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26.
Camlin Fine Sciences Ltd has issued a notice for its 33rd Annual General Meeting scheduled for August 11, 2026, to be held via video conferencing.
Camlin Fine Sciences Ltd has filed its Annual Report for the financial year 2025-26. The 33rd AGM is scheduled for August 11, 2026.
Camlin Fine Sciences completed a cash tender offer acquiring the remaining Vinpai shares, raising its holding to 95.41%. No financial amount is disclosed.
Camlin Fine Sciences announced the resignation of VP R&D Mr. Anvarhusen Bilakhiya, effective July 7, 2026. His departure follows a personal commitment, as per his resignation letter.
Camlin Fine Sciences reported Q4 revenue of ₹424cr and FY26 revenue of ₹1,723cr. Strategy focuses on shifting from 'Straights' to 'Blends' and scaling Vanillin production.
Camlin Fine Sciences submitted its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report indicates no material non-compliances or regulatory observations.
Camlin Fine Sciences appointed Pankaj Pandey as CFO, while current CFO Santosh Parab transitions to President - Strategy. New cost and internal auditors were also appointed.
CFS reported FY26 revenue of ₹17,233 mn (6% YoY growth) with an EBITDA margin of 6.2%. The company is pivoting towards high-value Blends and acquired Vinpai to diversify into natural ingredients.
Camlin Fine Sciences Ltd reported revenue from operations of ₹424.8 Cr (-1.6% YoY) and net profit of ₹86.3 Cr (+86200.0% YoY) for Q4 FY26.
Camlin Fine Sciences reported audited financial results for the year ended March 31, 2026. The board also appointed new executive leadership and internal auditors.
Camlin Fine Sciences reported a fire incident at its Dahej Diphenol Plant, causing ₹2 Crore in losses. Operations remain shut due to raw material supply constraints.
Camlin Fine Sciences scheduled a board meeting for May 26, 2026, to approve audited financial results. Trading window closure from April 1 remains in effect.
Camlin Fine Sciences shareholders approved an increase in authorized share capital via postal ballot with 99.99% majority. The resolution enables future capital raises and MoA amendments.
Camlin Fine Sciences Limited (CFSL) filed a draft simplified cash tender offer with the French AMF to acquire the remaining shares of Vinpai at EUR 3.60 per share. CFSL currently holds 83.82% of Vinpai's share capital and does not intend to implement a squeeze-out procedure.
Camlin Fine Sciences promoter Mr. Ashish Dandekar released a total of 40,96,000 pledged equity shares in two tranches on April 10 and 17, 2026. This follows partial repayment of borrowings to LRSD Securities Private Limited. Post-release, the promoter's total encumbered stake decreased from 9.92% to 7.78%.
Camlin Fine Sciences Ltd promoter Ashish S. Dandekar pledged 37,50,000 shares in total to Aditya Birla Capital and SKS Fincap. The encumbrance involves a ₹10 Crore loan facility to facilitate company borrowing and additional margin requirements. Total promoter encumbered shares now stand at 9.92% of the company's total share capital.
Camlin Fine Sciences Limited received an income tax demand notice of ₹5.47 Crore for Assessment Year 2023-24. The demand arises from Arm’s Length Price adjustments on international and domestic transactions with associated enterprises. The company intends to file an appeal against the order and states there is no immediate impact on operations.
Mr. Ashish Subhash Dandekar, promoter of Camlin Fine Sciences Ltd, pledged 6,50,000 equity shares (0.34% stake) in favor of Ashika Credit Capital Limited on March 30, 2026. This additional margin pledge was created to cover a shortfall in security cover for financial assistance obtained by the company.
Camlin Fine Sciences Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (DP) Regulations for the period ended March 31, 2026. The certificate, issued by MUFG Intime India, confirms that securities received for dematerialisation were processed and listed on the stock exchanges within prescribed timelines.